Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Exodus Technology Ltd. maintains 1 pending office action in the Biotechnology & Pharmaceuticals sector. The company's current patent prosecution is limited to 1 distinct examiner and 1 distinct art unit. This centralized structure indicates that all current legal efforts are focused on a specific point of contact at the patent office.
The busiest examiner for this portfolio is MEJIAS, SAMANTHA LEE, who is responsible for 1 busiest examiner pending action. Because this action constitutes the whole of the pending workload, the outcome of this interaction will define the company's immediate success in this technology area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MEJIAS, SAMANTHA LEE | 1 | 41.2% | +31.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035526 | SELECTIVE NERVE CELL DEACTIVATION | MEJIAS, SAMANTHA LEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035526 | SELECTIVE NERVE CELL DEACTIVATION | MEJIAS, SAMANTHA LEE | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18035526 | SELECTIVE NERVE CELL DEACTIVATION | MEJIAS, SAMANTHA LEE | 1618 | §102§103 | Non-Final OA | — | Pending | May 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialExodus Technology Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Samantha Lee Mejias has the most, with 1 of Exodus Technology Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.